Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcomaReport as inadecuate

Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma - Download this document for free, or read online. Document in PDF available to download.

Clinical Sarcoma Research

, 5:4

First Online: 24 January 2015Received: 13 November 2014Accepted: 19 December 2014DOI: 10.1186-s13569-014-0020-9

Cite this article as: Poon, V.I., Roth, M., Piperdi, S. et al. Clin Sarcoma Res 2015 5: 4. doi:10.1186-s13569-014-0020-9


BackgroundOsteosarcoma is the most common primary malignant bone tumor in children and young adults. Ganglioside GD2 has been previously found on the cell surface in various tumor types, including osteosarcomas.

FindingsIn this study, forty-nine additional osteosarcoma samples from 14 individual patients were assessed for GD2 expression via immunohistochemistry, of which 47 samples were found to express GD2. In matched samples from patients, GD2 expression seen at initial biopsy was found to persist in 100% of tissues taken at recurrence.

ConclusionsGD2 expression was found to persist upon recurrence. These results suggest a phase 2 trial in children with recurrent osteosarcoma should provide an appropriate read out on the efficacy of anti-GD2 antibody.

KeywordsOsteosarcoma Ganglioside GD2 Immunotherapy Antibody AbbreviationTMATissue microarray

Electronic supplementary materialThe online version of this article doi:10.1186-s13569-014-0020-9 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Vincent I Poon - Michael Roth - Sajida Piperdi - David Geller - Jonathan Gill - Erin R Rudzinski - Douglas S Hawkins - R



Related documents